โšกToday
โœจToday's leadDoctors Complete First Bone Marrow Transplant From Deceased Donor for Non-Malignant Disease๐ŸŽˆFor kidsSouth Carolina tract beside wildlife refuge to be permanently conserved๐ŸŒฟNatureFormer ocean liner S.S. United States becomes the world's largest artificial reefโšฝSportsLindy Duncan wins her first LPGA title on attempt 222๐ŸŽจCulture & ideasA Lost Altdorfer Landscape Surfaces After 70 Years Privately Held๐Ÿ”ฌScience & healthPeople who control HIV without treatment may help find a cure๐Ÿ’›KindnessA laid-off man began mowing lawns for free and 2,100 volunteers joined๐Ÿ›๏ธPoliticsLos Angeles bans oil drilling after a decade of neighborhood pressure๐Ÿš€ProgressPhiladelphia repaired a collapsed interstate in 12 days

Hong Kong start-up tests single-injection gene editing for inherited eye diseases

South China Morning Post 1 November 2026 5 min read

โฎ BeforeInherited eye diseases have limited treatment options.
โœ… NowA local start-up is testing a single-injection gene-editing therapy, still in testing.

In short

  • A local start-up is testing a gene-editing therapy for a group of inherited eye diseases.
  • The therapy aims to act on these diseases at their genetic source.
  • The article examines what it would take to turn the therapy into a treatment patients can access.

Why it's good news

Inherited eye diseases often have limited treatment options, so a therapy aimed at the genetic source is a meaningful direction. The source describes the work as testing and does not report approval or patient results. The piece focuses on the steps needed before patients could receive it.

Advertisement

From South China Morning Post

In the third of a four-part Health Matters wellness series on frontier medicine in Hong Kong, Fiona Sun examines how a local start-up is testing a gene-editing therapy that could tackle a group of inherited eye diseases at their genetic source and what it will take to turn it into a treatment patients can access. For 15 years, Professor Zheng Zongli has worked to make gene-editing therapies safe enough to treat diseases with limited treatment options. His path has taken him from a PhD in medical...

Read the full story at South China Morning Post Opens the publisher's site in a new tab.

Ask this story

An AI model answers from the material behind this story only, with a link to the source. Your question is sent to our AI provider and isn't stored. See Privacy.

More like this

Advertisement
AdMobile anchor